NCT07611838 Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
| NCT ID | NCT07611838 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qianfoshan Hospital |
| Condition | Allergic Bronchopulmonary Aspergillosis (ABPA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2021-01-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.
Eligibility Criteria
Inclusion Criteria: * Female and Male patients aged 18-80 years * diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria Exclusion Criteria: * Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.) * Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc. * Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents. * Pregnant or lactating women. * Patients with missing key data or incomplete medical records.
Contact & Investigator
Qian Qi
STUDY DIRECTOR
Shandong First Medical University
Frequently Asked Questions
Who can join the NCT07611838 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Allergic Bronchopulmonary Aspergillosis (ABPA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07611838 currently recruiting?
Yes, NCT07611838 is actively recruiting participants. Contact the research team at qiqianqlh@163.com for enrollment information.
Where is the NCT07611838 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT07611838 clinical trial?
NCT07611838 is sponsored by Qianfoshan Hospital. The principal investigator is Qian Qi at Shandong First Medical University. The trial plans to enroll 300 participants.